Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

34 trials with published results (27%)

Research Maturity

75 completed trials (59% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

8.6%

11 terminated out of 128 trials

Success Rate

87.2%

+0.7% vs benchmark

Late-Stage Pipeline

30%

39 trials in Phase 3/4

Results Transparency

45%

34 of 75 completed with results

Key Signals

34 with results87% success11 terminated

Data Visualizations

Phase Distribution

96Total
Not Applicable (30)
Early P 1 (2)
P 1 (8)
P 2 (17)
P 3 (29)
P 4 (10)

Trial Status

Completed75
Recruiting14
Withdrawn11
Terminated11
Unknown10
Active Not Recruiting4

Trial Success Rate

87.2%

Benchmark: 86.6%

Based on 75 completed trials

Clinical Trials (128)

Showing 20 of 20 trials
NCT05023382CompletedPrimary

A Study of Teduglutide in Japanese People With Short Bowel Syndrome

NCT03530852Not ApplicableRecruitingPrimary

A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB

NCT07714499Not ApplicableRecruiting

Resting Energy Expenditure by Gastrointestinal Functional Status

NCT07704047Phase 2RecruitingPrimary

A Clinical Study of FT1 in Patients With Short Bowel Syndrome

NCT05635747Enrolling By InvitationPrimary

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

NCT06973304Phase 3RecruitingPrimary

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

NCT06904872Phase 2RecruitingPrimary

Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)

NCT00169637Phase 3CompletedPrimary

Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome

NCT04775706Phase 2RecruitingPrimary

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT07197944Phase 3RecruitingPrimary

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT06512584Phase 3RecruitingPrimary

Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

NCT06771505RecruitingPrimary

SBS DISK- Creation of a Quality of Life Tool for Short Bowel Patients Compared With a Validated Quality of Life Questionnaire (SBS QoL)

NCT06326645Early Phase 1RecruitingPrimary

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

NCT04881825Phase 3Active Not RecruitingPrimary

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

NCT03905707Phase 3Active Not RecruitingPrimary

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

NCT06938542Not ApplicableEnrolling By Invitation

Palliative Care Needs of Children With Rare Diseases and Their Families

NCT07235670Not ApplicableCompletedPrimary

Gastrointestinal Hormone Secretion, Intestinal Permeability and Short Bowel Syndrome

NCT01990040Active Not RecruitingPrimary

Registry for Participants With Short Bowel Syndrome

NCT05535361Not ApplicableRecruitingPrimary

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

NCT07206004Not Yet RecruitingPrimary

Effect of Parenteral Support on FibroScan in Short Bowel Syndrome

Scroll to load more

Research Network

Activity Timeline